Skip to content
TrialScanner

NCT01403285

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Phase 1TerminatedIMTXLead

Registry record

Lead sponsor
Immatics Biotechnologies GmbH
Conditions
Glioblastoma
Primary completion
Apr 2014Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01403285 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01403285: Peptide-based Glioma Vaccine... | TrialScanner